Disclosure Of First-Time Adoption [Text Block]

Hyloris Pharmaceuticals SA - Filing #3166254

Concept	As at 2022-12-31	2022-01-01 to 2022-12-31	2022-01-01 to 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2022-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	As at 2021-12-31	2021-01-01 to 2021-12-31	2021-01-01 to 2021-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31
Disclosure of first-time adoption [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [text block]	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Disclosure of comparative information prepared under previous GAAP [abstract]
Disclosure of comparative information prepared under previous GAAP [line items]
Equity	55,045 EUR	—	—	476,000 EUR	4,460 EUR	121,513 EUR	1,622 EUR	64,246 EUR	140,000 EUR	54,805 EUR	476,000 EUR	—	—	48,056 EUR	—	3,827 EUR	103,693 EUR	2,391 EUR	—	129,000 EUR	—	—	43,226 EUR	129,000 EUR	3,827 EUR	476,000 EUR	1,814 EUR	103,693 EUR	59,059 EUR
Comprehensive income	—	10,770 EUR	10,770 EUR	—	—	—	—	—	—	—	—	- EUR	- EUR	—	- EUR	—	—	—	- EUR	—	11,579 EUR	11,579 EUR	—	—	—	—	—	—	—
Profit (loss)	—	10,770 EUR	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	11,579 EUR	—	—	—	—	—	—	—	—